Table 3.
Evidence that genetically engineered myeloid DC can prolong allograft survival or inhibit autoimmune disease
| Origin of DC | Gene transduced (method) | Regimen | Graft/disease | Reference |
|---|---|---|---|---|
| Transplantation | ||||
| Donor | FasL (lipofection) | Six postoperative i.p. injections of 5·106 DC | Heart | [104] |
| Donor | CTLA4Ig* (electroporation) | Twenty-five × 106 DC i.v. on day 0 and 6 | Pancreatic islets | [105] |
| Donor | TGFβ and IL-10† (adenovirus) | Portal venous injection of 5·106 DC 36 h before transplant | Kidney | [113] |
| Donor | CTLA4-Ig‡ (adenovirus) | Two × 106 DC i.v. 7 days before transplant | Heart | [114] |
| Donor | IL-10 (adenovirus) | i.p. injection of 106 DC autologous to the skin donor + allogeneic human PBMC | Human skin in NOD-SCID mice | [106] |
| Donor | IL-4 (retrovirus) | Two × 106 DC i.v. 7 days before transplant | Heart§ | [107] |
| Donor | TGFβ (retrovirus) | Two × 106 DC i.v. 7 days before transplant | Heart | [127] |
| Recipient | Donor MHC class I (adenovirus) | One month before transplant + anti-CD4 mAb | Heart | [115] |
| Autoimmune disease | ||||
| Autologous | IL-4 (adenovirus) | One × 106 DC i.v. to mice with established disease | CIA¶ | [116] |
| Autologous | IL-4 (retrovirus) | Three × 105 DC s.c., i.v. or i.p. to mice 15 days after collagen immunization | CIA | [117] |
| Autologous | FasL (adenovirus) | One × 106 DC i.v. to mice with established disease | CIA | [118] |
| Autologous | IL-4 (adenovirus) | Two × 5 × 105 DC i.v.to NOD mice at 10–11 weeks of age | Autoimmune diabetes | [119] |
*
DC cell line
†
1:1 mixture of DC transduced with either Ad IL-10 or Ad TGFβ
‡
adenoviral transduction of DC treated with NFκB antisense oligodeoxynucleotides
§
exacerbation of rejection
¶
CIA, collagen-induced arthritis.